Syneron Medical Ltd. (ELOS) was Downgraded by Leerink Partners to ” Mkt Perform”. Earlier the firm had a rating of “Outperform ” on the company shares. Leerink Partners advised their investors in a research report released on Aug 5, 2016.
On the company’s financial health, Syneron Medical Ltd. reported $0.09 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $0.06. The company had revenue of $75.00 million for the quarter, compared to analysts expectations of $75.72 million. The company’s revenue was up 2.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.07 EPS.
Syneron Medical Ltd. closed down -0.19 points or -2.70% at $6.86 with 2,05,556 shares getting traded on Thursday. Post opening the session at $7.18, the shares hit an intraday low of $6.61 and an intraday high of $7.18 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
Syneron Medical Ltd. is engaged in manufacture research development marketing and sales of advanced equipment for the aesthetic medical industry and systems for dermatologists plastic surgeons and other qualified practitioners. The Company designs develops and markets aesthetic medical products based on its various technologies including Electro-Optical Synergy (ELOS) technology to provide aesthetic medical treatments. The Company’s products targets an array of non-invasive aesthetic medical procedures including hair removal wrinkle reduction rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions acne treatment treatment of leg veins treatment for the temporary reduction in the appearance of cellulite and thigh circumference ablation and resurfacing of the skin laser-assisted lipolysis and topical skin brightening products.